

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6811131

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ANIRBAN KUNDU	02/20/2021
RECEIVING PARTY DATA	
Name:	EXUMA BIOTECHNOLOGY SEZC
Street Address:	90 N CHURCH STREET
City:	GEORGETOWN
State/Country:	CAYMAN ISLANDS
Postal Code:	KY1-1003
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17110028
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	561-650-5048
Email:	gschreiber@exumabio.com
Correspondent Name:	GREG SCHREIBER
Address Line 1:	625 N. FLAGLER DR., SUITE 625
Address Line 4:	WEST PALM BEACH, FLORIDA 33401
ATTORNEY DOCKET NUMBER:	F1.001.US.05
NAME OF SUBMITTER:	MICHAEL MAND
SIGNATURE:	/Michael Mand/
DATE SIGNED:	07/13/2021
Total Attachments: 3	
source=F1.001.US.05 Assignment Kundu to EXUMA SEZC#page1.tif	
source=F1.001.US.05 Assignment Kundu to EXUMA SEZC#page2.tif	
source=F1.001.US.05 Assignment Kundu to EXUMA SEZC#page3.tif	

ASSIGNMENT

FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency, and adequacy of which are hereby acknowledged, I/we:

1. Anirban Kundu, a citizen of India; having a mailing address of
204 Boltins Avenue, Apartment 8, West-Bay, Grand Cayman, Cayman Islands;
.....
and a resident of Grand Cayman, Cayman Islands.

do hereby SELL, ASSIGN, AND TRANSFER to EXUMA Biotechnology SEZC (the "Assignee", a corporation of The Cayman Islands) having a place of business at 90 N Church Street Georgetown, Grand Cayman, Cayman Islands, KY1-1003, the entire right, title, and interest for the United States and all foreign countries in and to:

(1) any and all inventions, improvements, know-how, and other subject matter described, disclosed, or contained (whether claimed or not) in (a) United States Patent Application, Serial No. 17/110,028 filed on December 2, 2020, entitled METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES TO EXPRESS POLYPEPTIDES COMPRISING THE INTRACELLULAR DOMAIN OF MPL, (b) all international, divisional, continuing, design, utility model, substitute, renewal, reissue, reexamination, and all other applications for patent which have been or shall be filed in the United States and all foreign countries that claim priority to or through, any of the foregoing applications; and (c) all original, reissued and reexamined patents which have been or shall be issued in the United States or any foreign country on or resulting from any of the applications referenced in (a) or (b);

(2) any and all inventions, improvements, know-how, and other subject matter described, disclosed, or contained (whether claimed or not) in any of the foregoing applications and patents;

(3) the right to file foreign applications under the provisions of any convention or treaty and claim priority based on any of the foregoing applications in the United States or any other country; and

(4) the copyright in any and all material described, disclosed, or contained in the foregoing applications and patents;

AUTHORIZE AND REQUEST the issuing authority to issue any and all United States and foreign patents granted on such improvements to the Assignee;

WARRANT AND COVENANT that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been or will be made to others by the undersigned, and that the full right to convey the same as herein expressed is possessed by the undersigned; and

COVENANT, when requested and at the expense of the Assignee, to carry out in good faith the intent and purpose of this assignment, the undersigned will (1) execute any and all papers and documents (including without limitation oaths, declarations, assignments, and powers of attorney) and perform any and all acts reasonably necessary in connection with the filing, prosecution, and issuance of each of the patent applications and patents referenced herein; (2) communicate to the Assignee all facts known to the undersigned relating to each of the patent applications, patents, and improvements referenced herein, and the history thereof; and (3) generally do everything possible that the Assignee shall reasonably consider desirable to vest title in Assignee in and to each of the patent applications, patents, and improvements referenced herein and for securing, maintaining, and enforcing proper patent protections for inventions, improvements, know-how, and other subject matter referenced herein.

TO BE BINDING on the heirs, assigns, representatives, and successors of the undersigned and extend to the successors, assigns, and nominees of the Assignee.

SEVERABILITY. If a provision of this Assignment is or becomes illegal, invalid, or unenforceable in any jurisdiction, that shall not affect (a) the validity or enforceability in that jurisdiction of any other provision of this Assignment, or (b) the validity or enforceability in other jurisdictions of that or any other provision of this Assignment.

Signature: Anirban Kundu

Date: FEB 20, 2021

Name (1): Anirban Kundu

Witness (1) Signature: Kausmik Chakraborty

Date: FEB 20, 2021

Witness (1) Name: KAUSMIK CHAKRABORTY

Assignee hereby acknowledges receipt of the entire right, title and interest in and to the intellectual property listed herein.

Signature: [Signature]

Date: JUNE 24, 2021

Signature of legal representative of EXUMA Biotechnology SEZC

James Samuels, President

EXUMA Biotechnology SEZC

Witness Signature: Deborah Shann

Date: JUNE 24, 2021

Witness Name: Deborah Shann